Shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) have received a consensus rating of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $13.00.
A number of analysts have recently issued reports on OSUR shares. Zacks Investment Research upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, March 1st. Lake Street Capital cut their target price on OraSure Technologies from $20.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, January 6th. TheStreet lowered OraSure Technologies from a “c-” rating to a “d+” rating in a research report on Friday, March 4th. Citigroup lowered their price target on OraSure Technologies from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, February 24th. Finally, StockNews.com lowered OraSure Technologies from a “hold” rating to a “sell” rating in a report on Thursday.
Shares of NASDAQ OSUR opened at $6.49 on Friday. The company has a quick ratio of 3.46, a current ratio of 4.24 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average price of $7.21 and a 200 day moving average price of $8.64. OraSure Technologies has a 1-year low of $6.45 and a 1-year high of $13.57.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Geneos Wealth Management Inc. raised its position in shares of OraSure Technologies by 203.1% during the third quarter. Geneos Wealth Management Inc. now owns 3,880 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 2,600 shares during the last quarter. Lazard Asset Management LLC boosted its position in OraSure Technologies by 72.8% during the fourth quarter. Lazard Asset Management LLC now owns 7,737 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 3,260 shares during the last quarter. CIBC Asset Management Inc bought a new stake in OraSure Technologies in the fourth quarter valued at approximately $92,000. Teacher Retirement System of Texas bought a new stake in OraSure Technologies in the third quarter valued at approximately $131,000. Finally, ARGI Investment Services LLC bought a new stake in OraSure Technologies in the third quarter valued at approximately $133,000. Hedge funds and other institutional investors own 98.74% of the company’s stock.
About OraSure Technologies (Get Rating)
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
- Get a free copy of the StockNews.com research report on OraSure Technologies (OSUR)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.